Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
- Paul M. Ridker
- Jean MacFadyen
- Brendan M Everett
- Peter Libby
- Tom Thurén
- Robert J. Glynn
- Paul M. Ridker
- Jean MacFadyen
- Brendan M Everett
- Peter Libby
- Tom Thurén
- Robert J. Glynn
- John J.P. Kastelein
- Wolfgang Köenig
- Jacques Genest
- Alberto Lorenzatti
- George Varigos
- Peter Siostrzonek
- Peter Sinnaeve
- Francisco Antônio Helfenstein Fonseca
- José Carlos Nicolau
- Nina Gotcheva
- Yong Huo
- Miguel Urina‐Triana
- Davor Miličić
- Renata Cífková
- Riina Vettus
- S.D. Anker
- Athanasios Manolis
- Fernando Wyss
- Tamás Forster
- Axel F. Sigurðsson
- Prem Pais
- Alessandro Fucili
- Hisao Ogawa
- HSHiroaki Shimokawa
- Irina Veze
- Birutė Petrauskienė
- Leon Salvador
- Jan H. Cornel
- Tor Ole Klemsdal
- Félix Medina
- Andrzej Budaj
- L Vida-Simiti
- Zhanna Kobalava
- Petar Otašević
- Daniel Pella
- Mitja Lainščak
- Ki‐Bae Seung
- Patrick Commerford
- Mikael Dellborg
- Marc Y. Donath
- Juey‐Jen Hwang
- Hakan Kültürsay
- Marcus Flather
- Christie M. Ballantyne
- Seth Bilazarian
- William H. Chang
- Cara East
- Les B. Forgosh
- Barry Harris
- M Ligueros
- HSHiroaki Shimokawa
The Lancet · 2017 · Elsevier BV
6 views · 0 downloads